Interrogating novel compounds for improved anti-dengue therapies via inhibition of human hexokinase II (HKII)
Dengue is one of the most fatal infectious diseases in the world, which is caused by dengue virus (DENV). Regrettably until now, specific treatment for the disease has not been established. It has been reported that a human glycolytic enzyme, the human hexokinase II (HKII) has a great impact in supp...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English |
| Published: |
2020
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/87224/1/Nanotech%20Symposium%202020%20Book%20Final%20-%20Fazia%20Nanotech%20Symposium%202020%20Book%20final.pdf http://irep.iium.edu.my/87224/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Dengue is one of the most fatal infectious diseases in the world, which is caused by dengue virus (DENV). Regrettably until now, specific treatment for the disease has not been established. It has been reported that a human glycolytic enzyme, the human hexokinase II (HKII) has a great impact in supporting viral replication in the host cell, thus the enzyme
has been proposed as an anti-DENV drug target. The main aim of this research is to identify novel anti-DENV agents for the treatment of dengue disease through in silico screening and HKII enzymatic inhibition studies. |
|---|